Omeros, which develops drugs for the treatment of surgery-related inflammation and pain, will see its quiet period end next Monday, Nov. 16. On October 7, 2009, the company raised $68.2 million by offering 6.8 million shares at $10.00, at the low end of the...read more
Four IPOs debuted this week, with Verisk Analytics the clear winner of the group. Verisk Analytics (VRSK), which provides data, statistical models and tailored analytics for P&C insurance firms, raised $1.9 billion by offering 85.3 million shares at $22.00,...read more
Though not quite the deal size magnitude the IPO market witnessed yesterday, volume continues as two new IPOs debut today. Mistras Group (MG), which provides non-disruptive infrastructure testing primarily to the energy market, raised $109 million by...read more
Omeros, which is developing drugs for the treatment of surgery-related inflammation and pain, raised $68 million by offering 6.82 million shares at $10, at low end of the proposed $10 to $12 range. Shares are expected to begin trading Thursday on the NASDAQ...read more
Omeros quiet period ends November 16
Omeros, which develops drugs for the treatment of surgery-related inflammation and pain, will see its quiet period end next Monday, Nov. 16. On October 7, 2009, the company raised $68.2 million by offering 6.8 million shares at $10.00, at the low end of the...read more
Verisk is this week's IPO winner
Four IPOs debuted this week, with Verisk Analytics the clear winner of the group. Verisk Analytics (VRSK), which provides data, statistical models and tailored analytics for P&C insurance firms, raised $1.9 billion by offering 85.3 million shares at $22.00,...read more
Mistras Group and Omeros are today's IPOs
Though not quite the deal size magnitude the IPO market witnessed yesterday, volume continues as two new IPOs debut today. Mistras Group (MG), which provides non-disruptive infrastructure testing primarily to the energy market, raised $109 million by...read more
Seattle-based biotech Omeros prices IPO at $10.00, at low end of the range
Omeros, which is developing drugs for the treatment of surgery-related inflammation and pain, raised $68 million by offering 6.82 million shares at $10, at low end of the proposed $10 to $12 range. Shares are expected to begin trading Thursday on the NASDAQ...read more